WuXi Biologics passes FDA inspection as WuXi Biologics stock nears yearly high

Published on 10/07/2026 at 02:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

WuXi Biologics passed an FDA inspection on October 5, 2026. An 18.40 percent first-half revenue rise matters for WuXi Biologics stock.

WuXi Biologics, KYG970081173, Illustration mit AI erstellt.

WuXi Biologics (ISIN KYG970081173) passed a two-week unannounced FDA inspection at its Wuxi Mashan facilities on October 5, 2026, while WuXi Biologics stock stood close to its 52-week high in Hong Kong. The inspection covered drug-substance and drug-product operations supporting multiple FDA-approved biologics, according to ChemicalsBlog.com on October 5, 2026.

FDA pass supports supply credentials

The Wuxi Mashan site combines drug-substance and drug-product manufacturing, giving the inspection direct relevance for commercial supply to the United States. The inspection result strengthens the companys quality narrative, but it does not remove geopolitical, trade or regulatory risks affecting Chinese manufacturing networks.

ChemicalsBlog.com reported that WuXi Biologics had passed 49 regulatory inspections by mid-2026, including inspections by the FDA and European Medicines Agency, and had completed more than 2,000 client GMP quality audits. Those figures put the October inspection into a broader operating context.

Revenue growth widens the base

For the six months ended June 30, 2026, revenue increased 18.40 percent year over year to RMB 11,787.2 million, while gross profit rose 28.10 percent to RMB 5,448.3 million, according to The Globe and Mail. The gross margin reached 46.20 percent, up 3.50 percentage points from the prior-year period.

Net profit for the first half of 2026 rose 5.80 percent to RMB 2,916.2 million, while net profit attributable to owners increased 4.30 percent to RMB 2,439.8 million. The gap between gross-profit growth and net-profit growth shows that operating improvement was partly offset below the gross-profit line.

Stock remains near yearly high

On the Hong Kong Stock Exchange, WuXi Biologics was last at HKD 57.90 on October 6, 2026 at 4:08 p.m. HKT, against a 52-week high of HKD 58.00. The price was 0.17 percent below that high, leaving the market valuation sensitive to execution, regulation and demand for late-stage biologics manufacturing.

Lang & Schwarz showed a prior close of EUR 6.55 for October 5, 2026. The further course of trading is shown by the continuously updated real-time quote of WuXi Biologics stock.